Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer

Daniel A. Monti; Edith Mitchell; Anthony J. Bazzan; Susan Littman; George Zabrecky; Charles J. Yeo; Madhaven V. Pillai; Andrew B. Newberg; Sandeep Deshmukh; Mark Levine

doi:10.1371/journal.pone.0029794

Loading metrics

Open Access

Peer-reviewed

Research Article

Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer

Daniel A. Monti,

Affiliation Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
Edith Mitchell,

Affiliation Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
Anthony J. Bazzan,

Affiliation Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
Susan Littman,

Affiliation Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
George Zabrecky,

Affiliation Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
Charles J. Yeo,

Affiliation Department of Surgery and the Jefferson Pancreas, Biliary, and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
Madhaven V. Pillai,

Affiliation Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
Andrew B. Newberg,

Affiliation Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
Sandeep Deshmukh,

Affiliation Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
⨯
Mark Levine

* E-mail: MarkL@mail.nih.gov

Affiliation Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
⨯

Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer

Daniel A. Monti,
Edith Mitchell,
Anthony J. Bazzan,
Susan Littman,
George Zabrecky,
Charles J. Yeo,
Madhaven V. Pillai,
Andrew B. Newberg,
Sandeep Deshmukh,
Mark Levine

Published: January 17, 2012
https://doi.org/10.1371/journal.pone.0029794

Reader Comments (1)

Post a new comment on this article

0 Responses

31 Jul 2012
23:33 GMT
Most Recent

Publisher's Note: Omission in Acknowledgements. Posted by PLOS_ONE_Group on 31 Jul 2012 at 23:33 GMT

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Vitamin C
Is the Subject Area "Vitamin C" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Pancreatic cancer
Is the Subject Area "Pancreatic cancer" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Computed axial tomography
Is the Subject Area "Computed axial tomography" applicable to this article?

Thanks for your feedback.
Lesions
Is the Subject Area "Lesions" applicable to this article?

Thanks for your feedback.
Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.